A total of 3307 thyroid FNABs were performed and interpreted at our institution between May 2010 and December 2014. Most of the FNABs were interpreted as being either benign (62.1%) or unsatisfactory (23.0%). There were 283 (8.6%) AUS/FLUS cases diagnosed, 95 (2.8%) sFN cases diagnosed, 54 sM cases diagnosed (1.6%), and 60 cancers (2.2%) diagnosed. The overall proportion of the study population with an indeterminate BSRTC diagnosis was 11.1%. Of the total number of individuals undergoing FNAB at our center, 291/3307 (8.8%) also underwent a thyroid operation at our center. Of these 291 cases, 15 (5.2%) FNABs were unsatisfactory, 76 (26.1%) were benign, 65 (22.3%) were AUS/FLUS, 54 (18.6 %) were sFN, 22 (7.5%) were sM and 59 (20.3%) were malignant (Table 1). Of the 65 AUS/FLUS cases, 11 underwent repeat FNAB. Nine of the repeat FNABs were again diagnosed as AUS/FLUS, and two were benign. Overall, of the 291 operated cases, 113 were diagnosed as cancer by histopathology, making the overall rate of malignancy in the study population 38.8%. The majority of the thyroid cancer cases were diagnosed by final histopathology as being PTC (101/113, 89.4%) and the remaining 12 (10.6%) cases were follicular carcinomas (FTC). Of the PTC cases 11 (10.9%) were subcategorized as the follicular variant of PTC. During the study period, there were two anaplastic carcinoma cases and that were diagnosed by FNAB. These cases were excluded from the study population in order to eliminate a potential source of bias, as they were all readily diagnosed by preoperative cytological assessment.